Investigation of Imatinib Pharmacogenomics in Patients With Gastrointestinal Stromal Tumor

Investigation of the Possible Role of Genetic Polymorphism on Both Plasma Level and Response of Imatinib in Patients With Gastrointestinal Stromal Tumor

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026010

Enrollment

Unknown

Registered

2019-09-17

Start date

2019-11-01

Completion date

Unknown

Last updated

2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal stromal tumor

Interventions

Case series:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years; 2. Documented diagnosis of GIST; 3. Imatinib treatment for at least 6 months; 4. Generally in good condition with no major organ disease; 5. Eastern Cooperative Oncology Group (ECOG) Performance Status Grade <= 3.

Exclusion criteria

Exclusion criteria: 1. Poor compliance to treatment; 2. Insufficient clinical data.

Design outcomes

Primary

Measure	Time frame
Genotype;Imatinib plasma level;Progression-free survival;Overall survival;	—

Secondary

Measure	Time frame
Complete response;Partial response;Oedema;Rash;Anemia;Conjunctival hemorrhage;Stable disease;	—

Countries

China

Contacts

Public ContactXiaoman Liu

The First Affiliated Hospital, Sun Yat-Sen University

only_for_work@sina.com+86 20 87608430

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026